cirmtuzumab

DRUG4 trials

Sponsors

Thomas Kipps, University of California, San Diego

Conditions

Chronic Lymphocytic LeukemiaMetastatic Castration-resistant Prostate Cancer

Phase 1

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

CompletedNCT02222688

Thomas KippsChronic Lymphocytic Leukemia

Start: 2014-08-08End: 2018-05-01Updated: 2020-08-13

Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961

CompletedNCT02860676

University of California, San DiegoChronic Lymphocytic Leukemia

Start: 2016-11-03End: 2018-05-22Updated: 2025-12-15

Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer

TerminatedNCT05156905

University of California, San DiegoMetastatic Castration-resistant Prostate Cancer

Start: 2022-06-16End: 2024-10-01Updated: 2024-10-09

Phase 2

Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax

Active, not recruitingNCT04501939

University of California, San DiegoChronic Lymphocytic Leukemia

Start: 2020-08-06End: 2026-07-22Updated: 2025-09-02

Related Papers

A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.

2024-11-014 citations

Abstract 5967: Blockade of Wnt5A/ROR1 signaling as cancer stem cell targeting therapy for metastatic prostate cancer

Cancer Research2024-03-22

Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax

Blood2020-11-041 citations

Ibrutinib + Cirmtuzumab in Patients With CLL/SLL or Mantle Cell Lymphoma

Oncology Times2020-03-12

A ROR1 Bispecific T Cell Engager for the Treatment of Chronic Lymphocytic Leukaemia Demonstrates Enhanced Function Following Ibrutinib Treatment

Blood2017-12-07